Mammograms for women in their 40s should be based on individual

April 02, 2007

STANFORD, Calif. -- Should all women in their 40s be routinely screened for breast cancer? Not necessarily, according to the American College of Physicians. In a new set of guidelines for clinicians of 40-something patients, the group recommends that mammography screening decisions be made on a case-by-case basis. It advises clinicians to discuss the benefits and harms of screening with the patient, as well as each woman's individual cancer risk and preference about screening.

The organization based its recommendations, which will be published in the April 3 issue of Annals of Internal Medicine, on a rigorous review of evidence showing there is variation in the benefits and harms associated with mammography among women in their 40s. The American College of Physicians is the leading professional organization for internal medicine specialists, with a membership of 120,000.

"There are important benefits to screening mammography, but we believe the decision to be screened should be based on an informed conversation between a patient and her physician," said health policy expert Douglas K. Owens, MD, MS, a researcher with the Veterans Affairs Palo Alto Health Care System and a professor of medicine at the Stanford University School of Medicine, who chaired the committee that developed the guidelines. "In our view, the evidence doesn't support a blanket recommendation for women in this age group."

Breast cancer is the second-leading cause of cancer related death among women in the United States; according to the American Cancer Society, 25 percent of all diagnosed cases are among women younger than age 50. Among these younger women, the risk of breast cancer varies greatly - from less than 1 percent for a 40-year-old woman with no risk factors to 6 percent for a 49-year-old woman with multiple risk factors, which include family history of breast cancer, older age at the birth of her first child and younger age at the onset of menstruation.

Physicians and medical groups have for years debated the merits of screening mammography for women in their 40s. While it is well-established that mammography reduces mortality from breast cancer in 50- to 70-year-old women - and that women in this age-group should be routinely screened - the evidence isn't as clear-cut for younger women.

Five years ago, the U.S. Preventive Services Task Force, an independent panel of experts in primary care and prevention, examined data from numerous clinical trials and estimated that screening mammography every one or two years in women in their 40s resulted in a 15 percent decrease in breast cancer mortality after 14 years of follow-up. But a separate Canadian study published in the same issue of the journal found that women in this age-group received no benefit from mammography.

Past analyses have also made note of the potential harms of screening, including radiation exposure, procedure-associated pain, false-positive results, over-diagnosis and potentially unnecessary treatment.

Based in part on the conflicting evidence, medical groups have differing screening recommendations for women under age 50. The U.S. Preventive Services Task Force and the American College of Obstetricians and Gynecologists both recommend screening mammography every one to two years for women in their 40s, while the 2006 American Cancer Society guideline recommends yearly mammograms starting at age 40.

Because of the ongoing controversy, the American College of Physicians' Clinical Efficacy Assessment Subcommittee decided to take its own look at the evidence related to screening in women in their 40s. After their review, the group concluded that screening mammography for women in this age group likely provides a modest reduction in breast cancer mortality, but - as with any screening intervention - it also comes with the risk of potential harms. Based on this, it recommended that clinicians:

In the new guidelines, the organization emphasizes the importance of using a woman's concerns about breast cancer and screening to help guide decision-making about mammography. Women's thoughts about mammography or their risks of developing breast cancer will likely vary greatly, the group notes, but it expects the potential reduction in breast cancer mortality associated with screening to outweigh other considerations for many women.

"We still think many women will choose to get mammography, and we're supportive of that," said Owens. "The most important thing is that women be well-informed about the decision they're making."
-end-
EMBARGOED FOR RELEASE UNTIL: Monday, April 2, 2007, at 2 p.m. Pacific time to coincide with publication in the Annals of Internal Medicine

PRINT MEDIA CONTACT: Margarita Gallardo at (650) 723-7897 (mjgallardo@stanford.edu)

BROADCAST MEDIA CONTACT: M.A. Malone at (650) 723-6912 (mamalone@stanford.edu)

Owens developed the guidelines in collaboration with Amir Qaseem, MD, PhD, MHA, and Vincenza Snow, MD, of the American College of Physicians; and colleagues from Drexel University College of Medicine, Beth Israel Deaconess Medical Center, Hines Veterans Affairs Hospital and Northwestern University, among others. Funding for the committee's work came from the American College of Physicians.

Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.

Stanford University Medical Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.